Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.

ABSTRACT:

Background

Atopic dermatitis (AD) is a common inflammatory skin disease with a global prevalence ranging from 3% to 20%. Patients with AD have an increased risk for complications after viral infection (eg, herpes simplex virus), and vaccination of patients with AD with live vaccinia virus is contraindicated because of a heightened risk of eczema vaccinatum, a rare but potentially lethal complication associated with smallpox vaccination.

Objective

We sought to develop a better understanding of immunity to cutaneous viral infection in patients with AD.

Methods

In a double-blind randomized study we investigated the safety and immunogenicity of live attenuated yellow fever virus (YFV) vaccination of nonatopic subjects and patients with AD after standard subcutaneous inocu

SUBMITTER: Slifka MK 

PROVIDER: S-EPMC3960337 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature